pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Oncology · news · pharmadog
← back to Oncology
News · Oncology
1,494
stories
24d
BioNTech says CTLA-4 drug nearly doubled survival times for lung cancer
endpoints
24d
AstraZeneca’s newly approved pill fails frontline breast cancer study
biopharma dive
24d
STAT+: How $500 explains Republican health policy, and the GLP-1 Rx wave
stat
24d
Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing
biopharma dive
24d
Summit, BioNTech, more headline WCLC with next-gen lung cancer drugs
biospace
24d
GSK heads to FDA with recently acquired drug from Nuvalent
endpoints
24d
Electra aims for nearly $300M IPO; Enhertu's Phase 3 lung cancer success
endpoints
25d
Pennsylvania officials report state’s third death involving measles
stat
25d
STAT+: GSK touts lung cancer data from two drugs
stat
25d
STAT+: Pharmalittle: We’re reading about another AstraZeneca trial failure, a Novo name change, and more
stat
25d
AstraZeneca’s newly approved cancer pill fails late-stage study, blocking path to bigger market
biospace
25d
Lilly cans early experimental obesity drug after ‘high bar’ not met
fiercebiotech
25d
Pennsylvania records third measles-related death amid outbreak
stat
25d
AstraZeneca’s next-gen SERD Etcamah disappoints in untreated advanced breast cancer
endpoints
25d
STAT+: Definium’s LSD therapy eased anxiety in second large trial
stat
25d
STAT+: What’s in a name? Novo looks to a rebrand
stat
25d
Electra aims for $342M IPO to power inflammatory drug’s push through phase 3
fiercebiotech
25d
The GOP’s $50 billion rural health fund is coming up short, hospital leaders say
stat
25d
Roche, MediLink notch phase 3 lung cancer win but trail GSK on cross-trial survival
fiercebiotech
25d
Unlocking cell surface protein research with site-specific labeling
biospace
25d
5 drugmakers chasing Merck and Moderna in the cancer vaccine race
biospace
25d
After a brief storm of political headwinds, mRNA is back with strong momentum
biospace
25d
Recon: New FDA oncology chief vows continued innovation in OCE; FDA approves drugs for two rare genetic diseases
raps
26d
GE HealthCare mulls $1B imaging chemicals maker deal: Financial Times
fiercebiotech
26d
Akeso details survival win for its PD-1xVEGF drug versus Keytruda
endpoints
27d
STAT+: Breast cancer pill from AstraZeneca misses mark in pivotal trial
stat
27d
STAT+: Scholar Rock wins FDA approval for first drug to target SMA muscle loss
stat
27d
STAT+: Pharma wins a battle over the cost of wastewater treatment in Europe
stat
27d
U.S. officials declare an end to record-setting cyclospora outbreak, but its origin is still unknown
stat
27d
FDA extends review of Exelixis' colorectal cancer drug candidate
endpoints
← prev
page 10 of 50
next →
